Literature DB >> 11340570

Optimization of differential photodynamic effectiveness between normal and tumor urothelial cells using 5-aminolevulinic acid-induced protoporphyrin IX as sensitizer.

J Seidl1, J Rauch, R C Krieg, S Appel, R Baumgartner, R Knuechel.   

Abstract

Photodynamic therapy using 5-aminolevulinic acid (5-ALA)-induced protoporphyrin IX is a promising tool in bladder-cancer therapy. However, little is known about the cellular mechanisms of phototoxicity. Our aim was to characterize the cellular damage and to optimize differential photodynamic effectiveness between tumor and normal urothelial cells. RT4 tumor and UROtsa normal urothelial cells were used to simulate a papillary bladder tumor in contrast to normal urothelium. Photodynamically induced damage in plasma membrane and mitochondria was monitored by flow cytometry with propidium iodide exclusion and analysis of aggregate formation of the dye JC-1. Cell morphology was investigated by phase-contrast and fluorescence microscopy following acridine orange staining. Long incubation times (3 hr) led to complete RT4 tumor cell kill accompanied by a marked fraction of damaged normal UROtsa cells. Shorter incubation intervals (1 hr) also resulted in complete RT4 tumor cell kill; however, most UROtsa cells retained their cell properties, including intact plasma membrane and active mitochondria as well as intact cellular morphology. Phototoxicity depends not only on cellular sensitizer accumulation but also on intracellular localization. Analysis of phototoxic mechanisms is an important step for planning combination therapy regimens with, e.g., DNA-damaging agents. Further, data indicate that differential phototoxicity in normal and tumorous urothelium can be enhanced using differences in cellular protoporphyrin IX distribution following short 5-ALA incubation times. These data are encouraging for the in vivo situation since short incubation times are a more practical approach for local photodynamic therapy of early tumor stages not only in the bladder but also, e.g., in the gastro-intestinal tract or bronchial mucosa. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11340570     DOI: 10.1002/1097-0215(20010601)92:5<671::aid-ijc1240>3.0.co;2-p

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  3 in total

1.  Low-dose methotrexate enhances aminolevulinate-based photodynamic therapy in skin carcinoma cells in vitro and in vivo.

Authors:  Sanjay Anand; Golara Honari; Tayyaba Hasan; Paul Elson; Edward V Maytin
Journal:  Clin Cancer Res       Date:  2009-05-15       Impact factor: 12.531

2.  Novel theranostic nanoporphyrins for photodynamic diagnosis and trimodal therapy for bladder cancer.

Authors:  Tzu-Yin Lin; Yuanpei Li; Qiangqiang Liu; Jui-Lin Chen; Hongyong Zhang; Diana Lac; Hua Zhang; Katherine W Ferrara; Sebastian Wachsmann-Hogiu; Tianhong Li; Susan Airhart; Ralph deVere White; Kit S Lam; Chong-Xian Pan
Journal:  Biomaterials       Date:  2016-07-22       Impact factor: 12.479

3.  Experimental investigation of a combinational iron chelating protoporphyrin IX prodrug for fluorescence detection and photodynamic therapy.

Authors:  Anette Magnussen; Charlotte Reburn; Alexis Perry; Mark Wood; Alison Curnow
Journal:  Lasers Med Sci       Date:  2021-07-04       Impact factor: 3.161

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.